SAN DIEGO, Sept. 11, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that Bertrand C. Liang, chief executive officer of Pfenex will be presenting at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 East 42nd Street, New York on September 18 at 2:10 pm ET. To access the live webcast link, please log on to www.pfenex.com.
Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
SOURCE Pfenex Inc.